#GU26 #ASCO Recap:
💥David McDermott, MD, Chief, Medical Oncology shared LITESPARK‑024 Phase 1/2 results in previously treated advanced #ccRCC
🏆 Hedyeh Ebrahimi, MD eoRCC multi‑omics study- earned @conquercancer.bsky.social Merit Award
🔑McDermott presented ccRCC Phase 2 KEYNOTE-427 tumor DNA data

Promising news from #GU26: Research led by @drchoueiri.bsky.social shows that adding #belzutifan to pembrolizumab adjuvant therapy prevented #ccRCC recurrence in high-risk patients better than pembrolizumab alone.

Learn more: https://bit.ly/3OxZdIE

Breaking news for people whose #KidneyCancer was not controlled by immunotherapy: Research led by Dr. Robert Motzer at #GU26 shows that #belzutifan + lenvatinib slows #ccRCC growth longer than cabozantinib.

Learn more: https://bit.ly/4aUKJtW

EORTC has opened the first site for the #RENALUT study, launching a Phase II evaluation of [177Lu]Lu‑PSMA‑617 in metastatic clear cell renal cell carcinoma after progression on prior treatments. More sites across Europe will follow.

🔗Read more: www.eortc.org/blog/2026/02...

#ccRCC #CancerResearch

☃️ It’s a pleasure to share today’s article from FEBSJ #Highlights2025. A perfect read for the weekend.

📕 CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression

Discover the article ➡️ buff.ly/qUo9aTH

#ccRCC #glycosaminoglycan #proteoglycan

This #STTT study identified a panel of seven blood-based protein #Biomarkers associated with TGF-β signaling and #Hypoxia that accurately detects #ccRCC, demonstrating the potential of liquid biopsies in diagnosis and target identification.

#OpenAccess: doi.org/10.1038/s413...

Deciphering genetic susceptibility to clear cell renal cell carcinoma - Communications Biology Integration of genome-wide association data with epigenomic and chromatin interaction data identifies target genes mediating clear cell renal cell carcinoma risk, implicating disrupted hypoxia signall...

We are pleased to present our manuscript on the annotation of clear cell Renal Cell Carcinoma #GWAS risk loci, recently published in @commsbio.nature.com

www.nature.com/articles/s42...

#ccRCC #cancer #genetics #genomics #KidneyCancer

📢 New publication alert!

EORTC’s RENALUT trial explores [177Lu]Lu-PSMA-617 in metastatic ccRCC. The protocol summary is now out in European Urology Oncology, highlighting radioligand therapy’s potential.

🔗 www.eortc.org/publications/

#EORTC #RENALUT #ccRCC

Cancer ‘Fingerprint’ Drives Vaccine Development | Cancer Today A vaccine based on a tumor’s unique genetic mutations leads to lasting immune response in locally advanced kidney cancer.

A small phase I trial led by @braunmdphd.bsky.social
studied a personalized vaccine for stage III/IV #kidneycancer
showed promise: at 40+ months, none of the 9 patients had recurrence + durable T-cell responses have continued.
cancertodaymag.org/fall-2025/ca...
@nature.com #ccRCC

SCI member Erinn Rankin & others show FTO, an RNA demethylase, drives glutamine reprogramming in #ccRCC, promoting growth. Inhibiting FTO disrupts metabolism, > DNA damage, and reduces survival, but pyrimidines/antioxidants rescue, highlighting FTO as a target. pubmed.ncbi.nlm.nih.gov/40532011/

Katie Coleman: Coffee with Chromies Is Back - OncoDaily Katie Coleman: Coffee with Chromies Is Back / cancer, chRCC, Chromophobe and Oncocytic Tumor Alliance, Katie Coleman, KCCure, kidney cancer, Kidney Cancer

Coffee with Chromies Is Back - Katie Coleman
@katiekickscancer.bsky.social
@kidney-cancer.bsky.social

oncodaily.com/positive/kat...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #KidneyCancer #ccRCC

Huge credit to André Figueiredo (PhD, Biochem
@laqv-requimte.bsky.social). Collaboration with @UPMC
fueling clinical impact.

📎 Full story: doi.org/10.1016/j.ta...
#Proteomics #ccRCC #pRCC #chRCC #Oncocytoma #CancerDiagnostics #PROTEOMICSNOVA

Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy We established a novel molecular classification for ccRCC via multiomics features, named multiomics subtype (MoS). MoS correlates with significantly different clinicopathological parameters, molecula...

#Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise #chemotherapy and #immunotherapy onlinelibrary.wiley.com/doi/full/10....
#ccRCC #Cancer #tumor #Bioinformatics

Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer

👉 buff.ly/D1G30KS

@drmeredithirwin

#ccRCC #CancerModels #KidneyCancer

Inceptor Bio Takes a Major Step in Clinical Trials for Cancer Therapy with New Funding Inceptor Bio has initiated clinical trials for IB-T101, a promising cancer treatment for ccRCC, supported by $21M funding. This milestone heralds a new era in cancer therapies.

Inceptor Bio Takes a Major Step in Clinical Trials for Cancer Therapy with New Funding #United_States #Research_Triangle_Park #Inceptor_Bio #IB-T101 #ccRCC